John PIERCE – Chairman of the board:
Throughout his career, John Pierce has focused on the integration of biology with chemistry, engineering, and material sciences to create biotechnological applications in agricultural chemistry, plant genetics, and industrial biology. He received a PhD in 1980 from Michigan State University in the areas of carbohydrate chemistry and enzymology. Most recently, he was the Chief Bioscientist for BP plc after a long period with DuPont during which he led the development of a number of commercially successful biotechnological applications.
John PIERCE – Chairman of the board:
Marc DELCOURT, CEO and Co-founder:
Global Bioenergies, Marc Delcourt is a former student of the Ecole Normale Supérieure, biology section. After completing a thesis in North America , it is towards R & D activities in the field of bioprocess and created in 1997 the first company in the field of industrial biology, Biométhodes. He left Biométhodes in 2008, then founded Global Bioenergies.
Philippe MARLIERE, Co-founder:
Philippe Marlière leads Global Bioenergies’ Scientific Advisory Board. He is a pioneer in the field of synthetic biology with his early work at the Pasteur Institute. He has since pursued his scientific work in several biotechnology companies that he has founded or cofounded. As a scientific partner of the CEA (largest French research organization for applied sciences) he advises the Director of Life Sciences in the fields of bioenergy and synthetic biology.
Sébastien GROYER, representing the investor Seventure Partners:
Sébastien Groyer is Partner at Seventure, a subsidiary of BPCE. Active since 1997, Seventure Partners has already made a number of investments in numerous technological domains. Sébastien Groyer, holds an Engineering degree in Biotechnologies from the Université Technologique de Compiègne and a Masters (DEA) in Politic and Economic Philosophy from Université Paris 1 Panthéon Sorbonne. He has participated in the investment in, the administration, the market launch or takeover of about 20 innovative companies, mostly in the domain of life sciences.
Karine LIGNEL – Permanent representative of CM-CIC INNOVATION :
Karine LIGNEL is a director at CM-CIC INNOVATION, a subsidiary of CM-CIC Capital Finance, Crédit Mutuel. CM-CIC Capital Finance focuses its investments on outstanding entrepreneurial companies, and has invested €2.6 billion in 620 companies. Karine LIGNEL has seven years of experience in the food industry, mainly in technical functions. A trained engineer (ENSIA – École Nationale Supérieure des Industries Agricoles et Alimentaires), Karine LIGNEL also has a Master’s Degree in Finance (IGIA, ESSEC). She joined venture capital in 2000 and invested mainly in Life Sciences. Since 2000, she has held numerous positions in the Boards of Directors and Supervisory Boards.
Alain Fanet has been an entrepreneur and executive for more than 20 years. He created two Franco-American companies in the high-tech sector: Arteris and T.sqware. He was recently Chairman and CEO of CXIgnited, an innovative company specialized in traceability of the supply channels in the luxury industry. Alain Fanet earned his PHD in Computer Science from ParisTech.
Pierre LEVI – Permanent representative of METMAN CAPITAL:
Pierre Lévi performed management functions in significant international groups, such as Groupe Salins (CEO), Faurecia (Chairman and CEO) or Rhône-Poulenc/Rhodia (Deputy President). He advises several innovative companies through his holding Metman Capital. Pierre Lévi is a graduate from Ecole des Mines of Paris and Warton School (MBA).